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Inflammation and endothelial activation are associated with an increased risk of CVD and epidemiological evidence suggests an association
between levels of markers of inflammation or endothelial activation and the intake of fruit. Also, vitamin E, a fat-soluble antioxidant, has anti-
inflammatory properties. We performed a randomised 2 £ 2 factorial, crossover trial to determine the effect of orange and blackcurrant juice
(500ml/d) and vitamin E (15mg RRR-a-tocopherol/d) supplementation on markers of inflammation and endothelial activation in forty-eight
patients with peripheral arterial disease. Patients were randomly allocated to two dietary supplements from the four possible combinations of
juice and vitamin E: juice þ vitamin E; juice þ placebo; reference beverage (sugar drink) þ vitamin E; and reference beverage þ placebo. The
supplementations were given for 28 d, separated by a 4-week wash-out period. Analysis of main effects showed that juice decreased C-reactive
protein (CRP) by 11% and fibrinogen by 3% while the reference drink increased CRP by 13% and fibrinogen by 2% (P,0·008 and P,0·002,
respectively). No significant differences were measured for IL-6 and the endothelial activation markers von Willebrand factor, tissue-plasminogen
activator and plasmin activator inhibitor-1. Vitamin E supplementation had no significant effects on the various markers. We observed no signifi-
cant interaction between juice and vitamin E. In this study, orange and blackcurrant juice reduced markers of inflammation, but not markers of
endothelial activation, in patients with peripheral arterial disease, relative to sugar drinks.
Fruit juice: Vitamin E: Inflammation: Oxidative stress: Peripheral arterial disease
Inflammation is an important mechanism for CVD, and
increased levels of inflammatory markers are seen in patients
with CVD, such as peripheral arterial disease (PAD). Further-
more, the plasma concentrations of acute phase reactants,
especially C-reactive protein (CRP) and fibrinogen, are associ-
ated with risk of myocardial infarction, ischaemic stroke, PAD
and cardiovascular death(1). In addition to being markers of
vascular inflammation, it has recently also been suggested
that CRP may causally contribute to atherosclerosis(2,3) indi-
cating that reduction in CRP concentration per se may be
clinically beneficial. This means that CRP concentrations
may be useful measures of the effectiveness of, for instance,
cardiovascular risk modifying lifestyle interventions(4).
Several studies indicate that a high intake of fruit and
vegetables is cardioprotective(5,6), an effect that is partly
explained by the antioxidative properties of the many bioactive
components including their influence on endothelial function(7).
In addition, studies suggest that the fat-soluble antioxidant vita-
min E has anti-inflammatory properties. However, the effect of
fruit and vegetables on CVD and inflammation(8–11) cannot
be explained by administering a high dose of antioxidants like
vitaminC orE as shown in large randomised, placebo-controlled
studies such as the Heart Protection Study(12), Women’s Anti-
oxidant Cardiovascular Study(13), Heart Outcomes Preven-
tion Evaluation Study(14) and HDL-Atherosclerosis Treatment
Study(15). These studies emphasise that it is yet too premature
to focus on high levels of specific vitamins, minerals or other
bioactive substances in the fruits and vegetables.
Since inflammation and endothelial function and activation
play key roles in the progression of atherosclerosis(16)
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therapeutic interventions that influence these processes, such
as antioxidant-rich foods, are of special interest. Fruit
juices are easily consumed and are, like the original fruits,
rich sources of various phenolic substances with antioxida-
tive properties including flavonoids and anthocyanidins
as well as vitamin C(17). Therefore, we investigated the
effect of orange and blackcurrant juices and low-dose
RRR-a-tocopheral (vitamin E) on the low-grade chronic
inflammation in patients with PAD during 4 weeks of sup-
plementation. In addition, the effects of juice and vitamin
E on markers of endothelial activation and oxidative stress
were investigated.
Methods
Patients
One hundred and forty-four patients with PAD were ident-
ified from the hospital records from the period 1999–2001
and contacted by mail. Forty-eight patients completed
both supplementation periods and were included in this
analysis. The participant flow is shown in Fig. 1 and
described earlier(18).
The study protocol was approved by the local Ethical
Committee of Ringkjøbing, Ribe and South Jutland Counties
(M-2242-01).
Study design
The study design has been described in detail previously(18).
Briefly, the study was a block-randomised, 2 £ 2 factorial
crossover trial with two intervention periods of 4 weeks and
one wash-out period of 4 weeks. During the intervention
periods, juice (250ml orange juice and 250ml blackcurrant
juice per day) þ vitamin E (15mg RRR-a-tocopherol/d)
(JE); juice þ placebo-vitamin E (JP); reference beverage þ
vitamin E (RE); or reference beverage þ placebo-vitamin E
(RP), were consumed by the patients. Each patient was allo-
cated to two of the four supplements(18). Investigators were
blinded for allocation and sequence. Patients were blinded
for tablet contents.
The vitamin E dose was selected to be equivalent to the
latest US dietary recommendation(19). The tablets used were
identical in appearance and prepared for this study by
Winter Medico A/S (Odense, Denmark). The selected juice
dose was based on the assumption that plasma vitamin C
may be used as a marker of fruit and vegetable intake(20)
and that 200mg, corresponding to an intake of the Danish rec-
ommendation of fruit and vegetables(21), results in plasma
ascorbate levels(22) that have been shown to be associated
with reduced risk of CVD(23). The reference beverage was a
sugar-containing beverage with energy content comparable
to the juices. The energy and carbohydrate content of the bev-
erages as well as the analysed ascorbic acid content of the
Fig. 1. Participant flow in the study.
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juices are shown in Table 1. Subjects were instructed to drink
250ml juice at breakfast and 250ml at dinner, and to take the
tablet at dinner. After each intervention period, the patients
were asked to return their leftovers for estimation of the appar-
ent adherence to treatment.
At baseline, usual intake of fruits, vegetables and juice were
assessed by a validated Danish FFQ(24). In addition, a self-
administered questionnaire was used to collect data on
smoking history, physical activity, medication use, pre-study
vitamin and/or antioxidant use and family history of CVD.
Weight in light clothing was measured before and after each
intervention period and height without shoes was measured
at baseline(18).
Blood collection and assessment of biomarkers
Subjects were examined twice, 3 d apart, at baseline and at
the end of each intervention period. Venous blood samples
were obtained with minimal stasis between 08.30 and 10.00
hours after a light breakfast. Within 1 h the specimens were
centrifuged to separate plasma/serum and samples were snap
frozen at 2808C until analysis. All six samples from one sub-
ject were analysed within the same run to prevent between-run
analytical variation. The specific handling of blood samples
has been described previously(18).
CRP concentrations were determined by particle-enhanced
immunonephelometry in accordance with the manufacturer’s
manual (DadeBehring, Germany). IL-6 concentrations were
measured by a high-sensitive enzyme immunoassay (R&D
Systems, UK), and functional fibrinogen was measured with
the Clauss method, an assay based on the clotting rate(25).
von Willebrand factor concentrations were determined by an
in-house EIA method (DAKO, Denmark). Plasminogen acti-
vator inhibitor-1 and tissue plasminogen activator concen-
trations were measured with the use of a commercial EIA
(Biopool, Umea˚, Sweden).
Free F2-isoprostane level was measured as a biomarker
of oxidative stress, i.e. lipid peroxidation. We expected that
the JE and RP would give the largest difference in this
measure of oxidative stress, and due to limited capacity we
analysed twenty-three samples that were randomly selected
from these two groups. The analyses were performed on
GC–MS with negative ion chemical ionisation as previously
described(26).
Compliance was assessed by measures of plasma concen-
trations of a-tocopherol and ascorbate using HPLC with
UV(27) and coulometric detection(28), respectively, as well as
tablet count. Non-fasting total-cholesterol, HDL and blood-
glucose were determined using standard routine methods in
the hospital laboratory.
Statistical analyses
Data were checked for Gaussian distribution with the
Shapiro–Wilks test and visual inspection of normplots. Non-
Gaussian-distributed data (CRP, fibrinogen, IL-6, plasminogen
activator inhibitor-1, vitamins C and E, and glucose) are pre-
sented as median and the 25th–75th percentile range, whereas
Gaussian-distributed data (von Willebrand factor, tissue plas-
minogen activator, total-cholesterol and HDL) are presented
as mean and standard deviation. CRP, fibrinogen, IL-6, and
plasminogen activator inhibitor-1 were Gaussian-distributed
after logarithmic transformation.
The effect of the supplementationswas described as the absol-
ute change in the particular variable (post-supplementation
value minus baseline values). The change was assessed in
an analysis of co-variance model with baseline value, supple-
mentation indicator and period effect as covariates together
with the cluster option, which takes into account that data are
not independent within clusters (i.e. each patient) due to the
cross-over design although independent across clusters.
Analyses were performed both for the individual groups
(JE, JP, RE, and RP) and for main effects (juice v. reference
beverage, and vitamin E v. placebo) in accordance with
the 2 £ 2 factorial design. Our primary reason for using a
factorial design was to make efficient use of the patients’
data, and the design also enabled us to estimate interaction.
Within-group changes from baseline to week 4 were ana-
lysed by the two-sided paired t test or the Wilcoxon matched
pairs signed rank sum test. A value of P,0·05 (two-tailed)
was taken to indicate statistical significance. Stata version
10.0 (Stata Corporation, Texas, USA) software was used for
statistical analyses.
We calculated that with forty-eight participants a statistical
power of at least 0·75 at significance level 0·05 is obtained test-
ing the global null hypothesis of no difference among all four
treatments (JE, JP, RE, RP) and the assumption that in any of
the three groups JP, JE, and RE two thirds of the subjects will
show a change in the same direction. This corresponds to an
expected change of at least 0·43 times the standard deviation
of the difference. Furthermore, it is assumed that there is no
change in the reference group (i.e. group RP) and that the
correlation of repeated measurements within a patient is at
least 0·25.
Results
Baseline characteristics of the study population are shown in
Table 2. No significant differences were seen in the baseline
characteristics among the four groups except for age that
was lower in the JP group (Table 2). Body weight, blood
lipids and blood glucose did not change during the study.
Among the forty-eight patients with PAD, 50% were
current smokers, who had initially higher levels of CRP
(3·39 v. 2·35mg/l, P¼0·002), fibrinogen (10·6 v. 9·7mmol/l,
Table 1. Energy, carbohydrate and vitamin C content in the provided
beverages*
Orange juice
(250 ml)
Blackcurrant
juice (250 ml)
Reference
drink (500 ml)
Energy (kJ) 450 675 1125
Carbohydrate (g) 25 36 67
Glucose (g) 9 3 13
Fructose (g) 7 3 23
Saccharose (g) 6 30 31
Vitamin C (mg)† 84·9 (SD 13·6) 124·8 (SD 26·2) 0
* Values are from the Danish Composition of Foods, 4th edition, and manufacturers’
information.
† Six different batches were analysed for each juice.
Fruit juices and inflammation 265
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https://doi.org/10.1017/S0007114508995660
Downloaded from https:/www.cambridge.org/core. Open University Libraryy, on 15 Jan 2017 at 22:31:47, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
P,0·001) and IL-6 (3·19 v. 2·44 pg/ml, P¼0·005) compared
with non-smokers.
Statins were used by 33%, aspirin by 77% and antihyper-
tensives (including angiotensin-converting enzyme inhibitors
and angiotensin II receptor blockers) by 33% of the patients;
medication did not change during the study. In addition, levels
of inflammation markers were not associated with the use of
medication.
Before the juice supplement, the patients had a habitual
median fruit and juice intake of 176 g/d, and a median
vegetables intake of 164 g/d. This habitual intake did not
change during the two intervention periods. At baseline, a
relationship (Spearman’s rank correlation coefficient) was
found between plasma concentrations of CRP and the esti-
mated daily fruit intake (rs 2 0·22, P¼0·04). In contrast, no
relationship was found between all other risk factors and the
daily intake of fruits or vegetables (P.0·2 for all).
Compliance
Forty-eight patients completed both periods. Plasma ascorbate
and a-tocopherol concentrations were similar when comparing
levels before intervention period 1 with levels before period 2
indicating that the wash-out period was sufficient (Table 3).
The observed increases in plasma ascorbate and a-tocopherol
concentrations indicate that the participants took their
supplementation regularly (Table 3). For a-tocopherol,
compliance was 96% by tablet count.
Inflammation and endothelial cell markers
The multivariate analysis showed significant differences only
for CRP changes among the four groups, i.e. the changes in
groups JE and JP were significantly different from the changes
in the reference group (i.e. RP). There were no significant
differences in analysis of interaction effects (P.0·05) and
results were independent of the vitamin E supplementation
(results not shown).
Themultivariate analysis of themain effects, i.e. juice v. refer-
ence beverage showed significant differences in CRP and fibri-
nogen only. Thus, after 4 weeks of orange and blackcurrant
juice supplementation, changes in plasma CRP and fibrinogen
concentrations were significantly different from changes in sub-
jects who received the reference beverage (CRP: 211% v.
þ13%, P,0·008; fibrinogen: 23% v. þ2%, P,0·002).
We observed no significant effect on IL-6 or the endothelial
cell markers (Table 4). We observed no significant differences
in any variable in patients who received vitamin E compared
with those who did not receive vitamin E (Table 4).
Significant relationship was seen between changes in CRP
and changes in fibrinogen (rs 0·63, P,0·0001). No relation-
ships were observed between all other biomarkers and changes
in plasma vitamins.
F2-isoprostane
Median percentage changes in plasma F2-isoprostane concen-
trations among patients in the reference þ placebo group (RP)
(16% (4–28%)) were significantly greater than those of
patients in the juice þ vitamin E group (JE) (210% (217
to 17%)) (P¼0·04, Mann–Whitney U test).
Discussion
In the present study in patients with PAD, CRP levels were
reduced by 11% after juice supplementation and increased
by 13% after supplementation with a reference beverage
that contained a similar amount of carbohydrates but no bio-
active components. Minor, but significant changes were also
observed for fibrinogen. Furthermore, our study confirms
that the plasma CRP concentration is inversely associated
with the intake of fruit in these patients.
Inflammation has a central role, not only in the initiation but
also in the progression of the atherosclerotic lesion and the
stability of the fibrous cap. CRP has been shown to be a sen-
sitive marker of the inflammatory activation of the vessel wall
and furthermore to associate well with cardiovascular-event
risk(29). CRP is also related to inflammation in other tissues
including adipose tissue(30). However, in the present study,
there were no indications of other underlying diseases or
changes in environment and lifestyle, including body weight
during the study period(18) that could affect levels of the
measured variables. Therefore, the observed reduction in
CRP may reflect a subdued inflammatory signalling that
eventually may slow down or stop the atherosclerotic pro-
gression(29,31). Furthermore, the changes in fibrinogen were
Table 2. Characteristics of participants at baseline
(Mean values and standard deviation, number and percentage, and median with 27th–75th percentiles as indicated)
Juice þ vitamin E
(JE, n 24)
Juice þ placebo
(JP, n 24)
Reference
beverage þ vitamin
E (RE, n 25)
Reference
beverage þ placebo
(RP, n 23)
Mean SD Mean SD Mean SD Mean SD
Age (years) 62·8 6·5 57·4 6·2 61·3 6·0 60·8 5·8
Females (n (%)) 9 (38) 8 (33) 7 (28) 2 (9)
Body weight (kg) 78·3 13·9 80·0 16·7 79·8 17·7 81·5 19·2
BMI (kg/m2) 27·0 3·7 26·9 4·4 27·0 4·5 27·2 5·1
Total cholesterol (mmol/l)* 5·7 1·0 5·4 0·9 5·8 0·8 5·8 0·8
HDL-cholesterol (mmol/l)* 1·6 0·6 1·4 0·3 1·4 0·5 1·4 0·5
Glucose (mmol/l)*† 5·7 (5·1–6·1) 5·7 (5·1–6·9) 5·8 (5·4–6·9) 5·9 (5·6–6·9)
* Non-fasting values.
† Data are presented as median and 25th–75th percentiles due to a non-Gaussian distribution.
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highly correlated with the CRP changes, which further sup-
ports that the supplementation affects a common underlying
inflammatory process. In contrast, we did not observe any
association between changes in blood levels of vitamin C
(or vitamin E) and CRP (or fibrinogen) which support the per-
ception that it is too early to ascribe the observed effects to
single nutrients.
CRP concentrations below 2mg/l are associated with 30%
lower risk of cardiovascular events compared with higher CRP
values(32) and in our study juice supplementation increased the
number of patients having a CRP concentration below 2mg/l
from 38 to 50%.
CRP and other acute phase proteins like fibrinogen are
synthesised in hepatocytes mediated by the action of the
pro-inflammatory cytokines IL-6, IL-1 and TNF, whose
expression is regulated by the activation of the pro-inflam-
matory transcription factor NF-kB(33). Studies have shown
that this activation is redox sensitive(34) and therefore is
activated by an increased level of reactive oxygen species.
In the present study, it is possible that the intake of either
beverage (both with high level of sugars) leads to an
increased intracellular concentration of glucose which is fol-
lowed by an increased reactive oxygen species production
that affects the level of inflammation(35,36). In contrast, the
presence of various bioactive molecules in the juices only
(like the antioxidants which are known to be bioavail-
able(37)) may counterbalance the potential reactive oxygen
species production. The results from the present study
support this notion, as we observed an increased level of
F2-isoprostane after sugar beverage þ placebo-vitamin E;
a change that was significantly different from the change
after juice þ vitamin E. However, although observed pre-
viously in female rats(38), a pro-inflammatory effect of a
sugar beverage was not confirmed in a smaller study in
obese but otherwise healthy human subjects(39). Thus, this
observation warrants further examination.
Table 3. Effects of a 4-week supplementation with orange and blackcurrant juices and vitamin E on plasma ascorbate and a-tocopherol concentrationsk
(Median values with 25th–75th percentiles (%ile))
Juice þ vitamin E
(JE, n 24)
Juice þ placebo-
vitamin E (JP, n 24)
Reference beverage þ
vitamin E (RE, n 25)
Reference beverage þ
placebo-vitamin E
(RP, n 23)
Median %ile Median %ile Median %ile Median %ile Main effect†
Ascorbate (mmol/l) Juice
Baseline 40·3 24·3 to 54·6‡ 46·4 28·8 to 60·9 47·3 32·3 to 69·4 31·5 18·9 to 51·6
Change§ 20·2*** 9·5 to 42·7 13·0** 0·1 to 24·2 25·9* 212·8 to 0·9 22·9 27·9 to 2·8 P,0·0001
a-Tocopherol (mg/ml) Vitamin E
Baseline 10·2 8·8 to 13·1‡ 9·9 8·3 to 11·7 10·8 9·5 to 12·3 10·8 9·1 to 12·9
Change§ 1·8** 1·1 to 2·4 20·4 20·8 to 0·7 0·8* 20·2 to 1·6 20·3 21·0 to 0·7 P,0·0001
Mean values were significantly different within the group: *P,0·05, **P,0·005, ***P,0·0001, all Wilcoxon matched-pairs signed rank sum test.
† Main effect comparing juice (JP þ JE) v. reference drink (RP þ RE), independent of vitamin E; or vitamin E (RE þ JE) v. placebo (RP þ JP), independent of juice.
‡ One blood sample for vitamins E and C analyses after supplementation was lost thus values represent n 23 subjects.
§ Change indicates difference between baseline and treatment in absolute values.
kFor details of supplementation see Methods.
Table 4. Main effects of 4-weeks supplementation with orange and blackcurrant juices or vitamin E on markers of inflammation and endothelial
function. The data show baseline values and changes (D) between baseline and treatment in absolute values†
(Values are median and 25th–75th percentile (%ile) or mean and 95 % CI)
Effect of juice Effect of vitamin E
Juice No juice Vitamin E N2o vitamin E
Median %ile Median %ile P-value* Median %ile Median %ile P-value*
CRP (mg/l) 2·8 1·2 to 4·8 2·6 1·3 to 4·5 2·8 1·1 to 4·7 2·5 1·3 to 4·6
DCRP 20·4 20·7 to 0·4 0·2 20·7 to 1·8 0·008 20·2 20·6 to 0·4 20·1 20·9 to 1·8 .0·1
Fbg (mmol/l) 10·2 8·9 to 11·1 10·4 9·0 to 11·2 10·3 9·1 to 10·9 10·2 8·9 to 11·4
DFbg 20·3 21·0 to 0·3 0·3 20·5 to 1·2 0·002 0·1 20·4 to 0·6 20·2 21·0 to 1·0 .0·1
IL-6 (pg/ml) 2·5 1·6 to 3·8 3·0 2·4 to 4·1 2·8 1·6 to 3·5 3·1 2·3 to 4·4
DIL-6 20·1 20·6 to 0·9 0·0 20·6 to 0·4 .0·1 0·1 20·6 to 0·5 20·1 20·6 to 0·7 .0·1
PAI-1 (ng/ml) 17·3 8·7, 37·5 19·4 7·2, 34·0 19·3 10·5, 37·5 17·2 6·0, 34·6
DPAI-1 0·4 25·4, 5·7 20·7 24·1, 5·5 .0·1 20·5 25·4, 5·3 0·3 24·6, 5·7 .0·1
Mean 95 % CI Mean 95 % CI Mean 95 % CI Mean 95 % CI
vWF (%) 150·8 139·2, 162·4 152·0 139·1, 164·8 149·4 136·7, 162·2 153·4 141·8, 165·0
DvWF 2·9 22·7, 8·5 4·6 22·9, 12·0 .0·1 1·5 25·3, 8·2 6·3 20·1, 12·6 .0·1
tPAag (ng/ml) 16·4 14·5, 18·2 17·2 15·7, 18·7 17·2 15·5, 19·0 16·3 14·7, 17·9
DtPAag 0·5 20·2, 1·3 0·2 20·8, 1·1 .0·1 0·0 20·8, 20·9 0·7 20·1, 1·5 .0·1
CRP, C-reactive protein; Fbg, fibrinogen; vWF, von Willebrand factor; tPAag, tissue plasminogen activator antigen; PAI-1, plasminogen activator inhibitor type 1.
*P-values are for main effect of differences in changes.
† For details of supplementation see Methods.
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It may seem surprising that CPR and fibrinogen change
while IL-6 did not change, as IL-6 is the main up-stream
determinant of the acute phase reactants(40). However, IL-6
is not the only determinant of the plasma levels of CRP and
fibrinogen(41), and taking into consideration the short IL-6
plasma half-life of about 3min(42), the large variability in cir-
culating IL-6 levels(43) and the presence of the soluble form of
the IL-6 receptor which binds the IL-6(44), these factors may
together with the small sample size and IL-6 assay character-
istics make it difficult to observe significant changes.
We also investigated the effect of 15mg a-tocopherol/d on
the selected biomarkers. The dose selected for the study corre-
sponds to the latest US recommendation(19) and it is even
higher than the Nordic recommendation(45). However, we
observed no effect on either the inflammatory or the endo-
thelial cell markers and the results thus supports the notion
that only very high un-physiological doses of vitamin E may
affect inflammation(46).
In this study population, 33–70% of the patients received
drugs that are known to have anti-inflammatory as well as
antioxidative capabilities. This has been clearly demonstrated
for statins(47–50), but also for several of the antihypertensive
drugs have anti-inflammatory effects been demonstrated(51).
However, the patients did not change their medication
during the study. Still, an interaction between medication
and juice or vitamin E cannot be excluded since our patient
groups were too small to determine this.
The habitual diet of the patients was supplemented with
more than 1MJ from the beverages, but their body weight
did not increase, which suggests that the patients may have
changed their diet and this may have influenced our results.
However, we do not expect that this would induce differences
in the effect on inflammatory responses between groups
because so far there is no evidence that juice and sugar bev-
erages induce different satiating effects.
Our study was a relatively small intervention study and
results should be replicated in larger study groups preferen-
tially with clinically relevant endpoints.
In summary, the use of blackcurrant and orange juices
reduces the level of the inflammatory markers CRP and fibri-
nogen in patients with PAD compared to a sugar-containing
beverage while no effect of vitamin E was observed. The
study supports the view that increased intake of fruit and veg-
etables, or products thereof, decreases the cardiovascular risk.
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